<DOC>
	<DOC>NCT01618916</DOC>
	<brief_summary>This is a phase 1 study in otherwise healthy participants with high LDL cholesterol. Following multiple doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body will be evaluated. Participants will participate in the study for approximately 3 months not including screening. Screening is required within 42 days prior to the start of the study.</brief_summary>
	<brief_title>A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol</brief_title>
	<detailed_description />
	<criteria>Participants must be healthy males or females without childbearing potential as determined by medical history and physical examination, including firstgeneration Japanese participants Have body mass indexes of 18 to 35 kg/m^2, inclusive, at screening Have screening lowdensity lipoprotein cholesterol (LDLCs) of between 100 and 180 milligrams per deciliter (mg/dL), inclusive Have known allergies to compounds related to LY3015014 or any components of the formulation or known clinically significant hypersensitivity to biologic agents Have a history of atopy, significant allergies to humanized monoclonal antibodies, clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin [Ig]A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis) Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, of constituting a risk when taking the study medication, or of interfering with the interpretation of data Have received any vaccine(s) within 1 month of LY3015014 dosing or intend to do so during the study Have received treatment with biologic agents (such as monoclonal antibodies) within 3 months or 5 halflives (whichever is longer) prior to dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>